Sahu Amiya Krushna, Sinha Vinod Kumar, Goyal Nishant
Department of Psychiatry, Centre for Cognitive Neurosciences, Central Institute of Psychiatry, Ranchi, Jharkhand, India.
Indian J Psychiatry. 2019 Mar-Apr;61(2):139-145. doi: 10.4103/psychiatry.IndianJPsychiatry_472_18.
The left dorsolateral prefrontal cortex (DLPFC) seems to exert a bilateral control of chronic pain states such as migraine. Repetitive transcranial magnetic stimulation (rTMS) is known to modulate brain excitability, neurotransmitters, and endogenous opioids involved in pathophysiology of migraine.
This study was designed to assess the efficacy of adjunctive intermittent theta-burst stimulation (iTBS) to the left DLPFC, as a prophylactic treatment in migraine.
The study was a double-blind, sham-controlled experiment. Patients with migraine were allotted to active ( = 20) or sham ( = 21) rTMS, respectively. Each patient received ten sessions of iTBS over the left DLPFC. Patients were rated at baseline and at 2, 4, 6, and 12 weeks after receiving the treatment. Scores were obtained from the headache diary and by applying the Migraine Disability Assessment Scale (MIDAS).
There was a significant decrease in frequency, duration, and severity of migraine in the active group than the sham group over the study period. The effect was more pronounced during the initial 2 weeks. The MIDAS score reduced significantly in the active group than the sham group at 12 weeks. There were no significant adverse effects observed during the entire period of study.
Compared to sham stimulation, adjunctive active iTBS over the left DLPFC was safe and effective in reducing the frequency, duration, and severity of migraine headache and in reducing disability associated with the illness.
左背外侧前额叶皮质(DLPFC)似乎对偏头痛等慢性疼痛状态发挥双侧控制作用。重复经颅磁刺激(rTMS)已知可调节参与偏头痛病理生理学的脑兴奋性、神经递质和内源性阿片类物质。
本研究旨在评估辅助性间歇性θ波爆发刺激(iTBS)作用于左侧DLPFC作为偏头痛预防性治疗的疗效。
该研究为双盲、假刺激对照实验。偏头痛患者分别被分配至活性rTMS组(n = 20)或假刺激组(n = 21)。每位患者在左侧DLPFC接受十次iTBS治疗。在基线以及接受治疗后的第2、4、6和12周对患者进行评分。通过头痛日记和应用偏头痛残疾评估量表(MIDAS)获得分数。
在研究期间,活性组偏头痛的频率、持续时间和严重程度较假刺激组有显著降低。在最初2周内效果更为明显。在12周时,活性组的MIDAS评分较假刺激组显著降低。在整个研究期间未观察到显著不良反应。
与假刺激相比,辅助性活性iTBS作用于左侧DLPFC在降低偏头痛发作频率、持续时间和严重程度以及减轻与疾病相关的残疾方面是安全有效的。